ClinicalTrials.Veeva

Menu
S

Sarcoma Oncology Research Center | Santa Monica, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Nivolumab
Ipilimumab
Doxorubicin
Lurbinectedin
PM01183
SP-2577
Nab-sirolimus
ABI-009
Gemcitabine
SM-88

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 53 total trials

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.Estimate the maximum tolerated dose...

Active, not recruiting
KRAS p.G12C Mutant Advanced Solid Tumors
Drug: Anti PD-1/L1
Drug: sotorasib

The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.

Active, not recruiting
Desmoid Tumor
Desmoid
Other: Placebo
Drug: AL102

This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in comb...

Enrolling
Mucosal Melanoma
Malignant Peripheral Nerve Sheath Tumors (MPNST)
Drug: Phase 1b: APG-115+pembrolizumab

This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatm...

Enrolling
Glioblastoma
Glioblastoma Multiforme
Other: Vitamin K1
Drug: BPM31510

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic...

Active, not recruiting
Isocitrate Dehydrogenase Gene Mutation
Drug: HMPL-306

The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the...

Enrolling
Advanced Solid Tumors
Drug: Gemcitabine
Drug: ADCT-601

This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or me...

Active, not recruiting
Leiomyosarcoma
Other: Placebo
Drug: Dacarbazine

Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chro...

Active, not recruiting
Primary Pulmonary Myxoid Sarcoma
Sclerosing Epithelioid Fibrosarcoma
Drug: Seclidemstat
Drug: Topotecan

This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafo...

Active, not recruiting
Myxofibrosarcoma
Undifferentiated Pleomorphic Sarcoma
Drug: Ipilimumab
Biological: Envafolimab

This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in combination with Opdivo (nivilumab) for the treatment patients wi...

Active, not recruiting
Solid Tumor, Adult
Small Cell Lung Cancer
Drug: Nivolumab Injection
Drug: AL3818

Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for...

Active, not recruiting
Breast Cancer
Solid Tumor, Adult
Drug: Imx-110

Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered iv...

Enrolling
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Drug: Placebo
Drug: Ivosidenib 500mg

This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of...

Active, not recruiting
Aggressive Fibromatosis
Desmoid Tumor
Drug: Placebo Oral Tablet
Drug: Nirogacestat oral tablet

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting
Solid Tumor
Malignant Neoplasm
Drug: nab-sirolimus

This is an open label, dose-seeking phase 1/2 study using escalating doses of TRABECTEDIN given intravenously with defined doses of IPILIMUMAB and NI...

Enrolling
Metastatic Soft Tissue Sarcoma
Advanced Soft Tissue Sarcoma
Drug: Nivolumab
Drug: Ipilimumab

The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, in two study cohorts:* Clinically advanced Ewin...

Active, not recruiting
Sarcoma
Sarcoma, Ewing
Drug: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)

BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomize...

Enrolling
Solid Tumor
Drug: BBI-825

The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bon...

Enrolling
Advanced Epithelioid Sarcoma
Advanced Soft-tissue Sarcoma
Drug: Doxorubicin HCl
Drug: Tazemetostat

Trial sponsors

S
Amgen logo
F
A
B
Pfizer logo
P
S
A
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems